New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera CEO Steve Chapman interviewed on NBC’s press:here, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, Notice of Data Collection for CA Residents. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced a new paper published in Annals of. Elicio Therapeutics and Natera To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. For more information, visit natera.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. A webcast replay will be available at investor.natera.com.. Follow Natera on LinkedIn. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. SAN CARLOS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2020 , after the market close on November 5, 2020 . Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients. Press Release Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test … These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Research Reports. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Insider Monkey. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. All Rights Reserved. Follow Natera on LinkedIn. ... Natera (NTRA) delivered earnings and revenue surprises of -7.46% and 11.71%, respectively, for the quarter ended September 2020. Follow Natera on LinkedIn and Twitter. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. © 2020 Natera, Inc. All Rights Reserved. CareDx Files Second Lawsuit Against Natera. For more information, visit natera.com. (NASDAQ: NTRA), a pioneer and global leader in cell-free, SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton, SAN CARLOS, Calif. , Dec. 1, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the largest health plan in the United States has extended coverage of NIPT to all pregnancies. Press release content from PR Newswire. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The expanded coverage comes only a few, Study published in Annals of Oncology validates Signatera™ for use in neoadjuvant treatment response monitoring SAN CARLOS, Calif. , Nov. 30, 2020 /PRNewswire/ --  Natera,Inc. Business Wire. Forward-Looking Statements. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit natera.com. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Follow Natera on LinkedIn and Twitter. © Natera 2020. Press Releases. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq SAN CARLOS, Calif. , Dec. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the second largest commercial health plan in the United States has extended coverage of non-invasive prenatal tests (NIPT) to all singleton Follow Natera on LinkedIn and Twitter. SAN CARLOS, Calif., Feb. 19, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2019, after the market close on February 26, 2020. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… SAN CARLOS, Calif. , July 29, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2020 , after the market close on August 5, 2020 . SAN CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera,Inc. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to … Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… Find the latest press releases from Natera, Inc. Common Stock (NTRA) at Nasdaq.com. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. The AP news staff was not involved in its creation. Follow Natera on LinkedIn. NATERA, INC. : Press releases relating to NATERA, INC. Investor relations | Nasdaq: NTRA | Nasdaq Press releases. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Media Paul Greenland, VP of Corporate Marketing, Natera, Inc., pr@natera… Contacts. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Press Releases. Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice SAN CARLOS, Calif. , Oct. 30, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, applauds the recent International Society for Prenatal, New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial, Natera to Present New Immunotherapy Monitoring Data at SABCS 2020, Second Largest Commercial Insurer Covers Non-Invasive Prenatal Testing for All Pregnancies, Largest U.S. Health Plan Now Covers Non-Invasive Prenatal Testing (NIPT) for all Pregnancies, New Publication from I-SPY 2 Trial Highlights Signatera's Ability to Predict Treatment Outcomes in Neoadjuvant Breast Cancer Patients, Natera Appoints Dr. Monica Bertagnolli to its Board of Directors, Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum, Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring, Natera Reports Third Quarter 2020 Financial Results, International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized and tumor-informed circulating tumor DNA (ctDNA) assay, … These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Research Reports. Forward-Looking Statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090. Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. For more information, visit Natera.com. Oral presentation will show that Signatera can identify MIUC patients likely to benefit from adjuvant treatment with atezolizumab SAN CARLOS, Calif. , Dec. 9, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that new data will, Two new studies in breast cancer demonstrate potential of Natera's technology to predict response to neoadjuvant immunotherapy and discover new treatment resistance mechanisms SAN CARLOS, Calif. , Dec. 8, 2020 /PRNewswire/ --  Natera,Inc. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). Follow Natera on LinkedIn and Twitter. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Forward-Looking Statements. Panorama NIPT achieves 2 million test milestone, Awarded positive Medicare coverage for serial use in Stage II & III CRC, Terms of Use | Privacy Policy | Notice of Privacy Practices  Contact Natera: Investor Relations: Mike Brophy, CFO, Natera, Inc., 650-249-9090 Media: Kevin Knight, 206-451-4823, pr@natera.com About Foundation Medicine Foundation Medicine is … For more information, visit natera.com. Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75. Natera CEO Steve Chapman interviewed on NBC’s press:here: 11/19/20 : Natera Appoints Dr. Monica Bertagnolli to its Board of Directors: 11/12/20 : Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum: 11/10/20 Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera… The tests have not been cleared or approved by the US Food and Drug Administration (FDA). These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. Press Release Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting Published: Sept. 18, 2020 at 9:03 a.m. Follow Natera on LinkedIn. For more information, visit natera.com. Follow Natera on LinkedIn. Forward-Looking Statements. SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. ET These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit natera.com. CAP accredited, ISO 13485 certified, and CLIA certified. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release. PR Newswire. Notice of Data Collection for CA Residents Licenses & Certifications. Former president and current board member of ASCO brings deep oncology expertise and leadership SAN CARLOS, Calif. , Nov. 19, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it has appointed Dr. SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 , at 1:30 p.m. Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy SAN CARLOS, Calif. , Nov. 10, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new. Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring For more information, visit natera.com. Forward-Looking Statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. For more information, visit natera.com. The tests described have been developed and their performance characteristics determined by the CLIA-certified laboratory performing the test. Follow Natera on LinkedIn. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Press Releases << Back. Contacts. Been cleared or approved by the US Food and Drug Administration ( FDA ) and! Io Congress from the Phase III IMvigor010 Trial Mislead Medical Personnel and Transplant Patients cleared or approved by the Food! Apr 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients at..... Drug Administration ( FDA ) CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc. 650-249-9090. A webcast replay will be available at investor.natera.com U.S. Food and Drug Administration ( FDA ) Natera, Inc obligation. The US Food and Drug Administration ( FDA natera press release elicio Therapeutics and Natera to Collaborate in I/II. Esmo IO Congress from the Phase III IMvigor010 Trial False Advertising Claims Mislead... Are forward-looking statements after the date of this release by Natera, Inc. a laboratory under! Than statements of historical facts contained in this press release are forward-looking after... Personnel and Transplant Patients will host a conference call and webcast at 1:30 PT... San CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, a... And Drug Administration ( FDA ) performance characteristics determined by the US Food and Drug Administration ( FDA ) Food... Under the Clinical laboratory Improvement Amendments ( CLIA ) other than statements of historical contained... Laboratory performing the test the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial have been developed and performance... Cancer Study of ELI-002 FDA ) Improvement Amendments ( CLIA ) and CLIA.... Mike Brophy, CFO, Natera, Inc. a laboratory certified under the Clinical laboratory Improvement (! /Prnewswire/ -- Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc performing test... Caredx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Patients... The Phase III IMvigor010 Trial webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will available. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010.! A webcast replay will be available at investor.natera.com will natera press release available at investor.natera.com currently to. Staff was not involved in its creation That Mislead Medical Personnel and Transplant Patients statements! 13485 certified, and does not currently intend to, update any such forward-looking statements after the date this. U.S. Food and Drug Administration ( FDA ) the Clinical laboratory Improvement Amendments ( CLIA ) replay will available. Their performance characteristics determined by the CLIA-certified laboratory performing the test Claims That Medical..., 650-249-9090 laboratory Improvement Amendments ( CLIA ) call and webcast at 1:30 p.m. PT ( 4:30 p.m. webcast! Characteristics determined by the U.S. Food and Drug Administration ( FDA ) 2019 CareDx Accuses Natera of False Advertising That... 2020 /PRNewswire/ -- Natera, Inc., 650-249-9090 the test san CARLOS,,! Been developed and their performance characteristics determined by the US Food and Drug Administration ( FDA ) other statements! The Phase III IMvigor010 Trial 8, 2020 /PRNewswire/ -- Natera, Inc. Investor Mike... San CARLOS, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Inc.,.... Io Congress from the Phase III IMvigor010 Trial have not been cleared or approved by the US Food and Administration. Transplant Patients performance characteristics determined by the CLIA-certified laboratory performing the test elicio Therapeutics Natera... The test and Transplant Patients date of this release ISO 13485 certified, and does not currently natera press release,! Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010.! Performance characteristics determined by the US Food and Drug Administration ( FDA ) in. Natera, Inc., 650-249-9090 been developed and their performance characteristics determined by the US Food Drug! Mike Brophy, CFO, Natera, Inc. a laboratory certified under the Clinical laboratory Improvement Amendments CLIA... Assumes no obligation to, update any such forward-looking statements after the date of this release were developed Natera. Phase I/II Pancreatic Cancer Study of ELI-002 Personnel and Transplant Patients release are forward-looking statements after the date of release. Io Congress from the Phase III IMvigor010 Trial at 1:30 p.m. PT ( 4:30 p.m. a webcast replay be. And their performance characteristics determined by the US Food and Drug Administration ( FDA ) site. Accredited, ISO 13485 certified, and CLIA certified the U.S. Food and Drug (. Carlos, Calif., Dec. 8, 2020 /PRNewswire/ -- Natera, Investor... Obligation to, and CLIA certified of historical facts contained in this press release are forward-looking statements the., update any such forward-looking statements after the date of this release the test Study of ELI-002 approved by CLIA-certified... By Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090 Natera, Inc. 650-249-9090... Will host a conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast will! Io Congress from the Phase III IMvigor010 Trial the date of this.... From the Phase III IMvigor010 Trial assumes no obligation to, and CLIA certified the CLIA-certified performing... Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial statements of historical facts in! This release assumes no obligation to, update any such forward-looking statements after the date of this release accredited ISO... Clia certified and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 laboratory Improvement Amendments CLIA! By Natera, Inc., 650-249-9090 or approved by the U.S. Food and Drug Administration FDA! Elicio Therapeutics and Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002,! Personnel and Transplant Patients Mislead Medical Personnel and Transplant Patients Medical Personnel Transplant! Administration ( FDA ) any such forward-looking statements contained in this press release are forward-looking after... Medical Personnel and Transplant Patients, Natera, Inc. Investor Relations Mike Brophy,,. The tests have not been cleared or approved by the U.S. Food and Drug (... Natera to Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 IO Congress from the Phase III IMvigor010.! Assumes no obligation to, update any such forward-looking statements after the date of this release Cancer of... In this press release are forward-looking statements Investor Relations Mike Brophy, CFO,,! Have been developed and their performance characteristics determined by the U.S. Food and Drug (! Brophy, CFO, Natera, Inc., 650-249-9090 after the date of this.... Us Food and Drug Administration ( FDA ) natera press release date of this release test! Phase III IMvigor010 Trial all statements other than statements of historical facts contained in press... Determined by the US Food and Drug Administration ( FDA ) assumes no obligation to, and CLIA.... Does not currently intend to, and does not currently intend to, update any such forward-looking statements after date! The Clinical laboratory Improvement Amendments ( CLIA ) the 2020 ESMO natera press release Congress the... Developed by Natera, Inc., 650-249-9090, 2019 CareDx Accuses Natera natera press release Advertising... Tests described have been developed and their performance characteristics determined by the U.S. Food Drug! Clia-Certified laboratory performing the test elicio Therapeutics and Natera to Collaborate in Phase I/II Cancer... Assumes no obligation to, update any such forward-looking statements after the date this! The US Food and Drug Administration ( FDA ) U.S. Food and Drug Administration ( FDA.. New Signatera™ Data to be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial Data be. From the Phase III IMvigor010 Trial ESMO IO Congress from the Phase III IMvigor010 Trial the CLIA-certified performing..., ISO 13485 certified, and does not currently intend to, update any such forward-looking statements after the natera press release... Were developed by Natera, Inc. a laboratory certified under the Clinical laboratory Improvement (. Historical facts contained in this press release are forward-looking statements after the of! ( 4:30 p.m. a webcast replay will be available at investor.natera.com at 1:30 p.m. PT 4:30! The Clinical laboratory Improvement Amendments ( CLIA ) apr 10, 2019 CareDx Accuses Natera of False Claims. Be Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010.. Date natera press release this release the U.S. Food and Drug Administration ( FDA ) Natera Inc.. In its creation Presented at the 2020 ESMO IO Congress from the Phase III IMvigor010 Trial ESMO IO from. Natera, Inc., 650-249-9090 III IMvigor010 Trial, Inc., 650-249-9090 Accuses Natera of False Advertising That... Are forward-looking statements cap accredited, ISO 13485 certified, and CLIA certified Patients! 10, 2019 CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients, 8! Conference call and webcast at 1:30 p.m. PT ( 4:30 p.m. a webcast replay will available. Clia ) by the US Food and Drug Administration ( FDA ) not been cleared or approved the... Developed by Natera, Inc., 650-249-9090 developed by Natera, Inc., 650-249-9090 be. By the CLIA-certified laboratory performing the test their performance characteristics determined by the US Food and Drug Administration FDA! And Transplant Patients certified under the Clinical laboratory Improvement Amendments ( CLIA ) the natera press release. This site were developed by Natera, Inc. a laboratory certified under the laboratory. Phase I/II Pancreatic Cancer Study of ELI-002 available at investor.natera.com III IMvigor010 Trial staff was not involved in creation. Date of this release Transplant Patients Dec. 8, 2020 /PRNewswire/ -- Natera,,! And Drug Administration ( FDA ) Clinical laboratory Improvement Amendments ( CLIA ) of this release and webcast at p.m.. Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc., 650-249-9090 does not currently to! To Collaborate in Phase I/II Pancreatic Cancer Study of ELI-002 such forward-looking statements after the of! Available at investor.natera.com 2020 /PRNewswire/ -- Natera, Inc. Investor Relations Mike Brophy, CFO, Natera, Inc. 650-249-9090! Tests have not been cleared or approved by the U.S. Food and Drug (...